Articles from TherapeuticsMD, Inc.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022.

TherapeuticsMD, Inc. (NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products in the United States. In addition, TXMD sold certain assets to Mayne Pharma to enable it to commercialize the products.

TherapeuticsMD, Inc. (NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products.

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2022.

TherapeuticsMD, Inc. (NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received an additional $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital.

TherapeuticsMD, Inc. (NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received a $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction for working capital.

TherapeuticsMD, Inc. (NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O’Dowd as the Company’s Chief Executive Officer.

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022.

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets.

TherapeuticsMD, Inc. (NASDAQTXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it has received a $15 million private investment in the Company’s common stock and a new series of preferred stock (“PIPE”) from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction to fulfill its near-term operating capital requirements.

TherapeuticsMD, Inc. (NASDAQTXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that Athene Merger, Inc., an affiliate of EW Healthcare Partners (“EW”), did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended offer deadline of one minute after 11:59 PM Eastern Time on July 12, 2022. As a result, the tender offer has expired according to its terms. The Company anticipates that the Merger Agreement between TXMD and EW will be terminated pursuant to its terms following 11:59 PM Eastern Time on July 13, 2022.

TherapeuticsMD, Inc. (NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies.

TherapeuticsMD, Inc. (NASDAQTXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA. The sNDA included minor revisions to ANNOVERA’s in vitro release testing specification that allowed for normal manufacturing variability.

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the first quarter ended March 31, 2022.

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today announced that it will report its first quarter 2022 financial results on Monday, May 16, 2022, after the closing of the U.S. financial markets.

TherapeuticsMD, Inc. (NASDAQTXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx NASDAQ: GDRXNASDAQGDRX)

TherapeuticsMD, Inc. (NASDAQTXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturing testing limits. The Company will continue to manufacture and supply ANNOVERA under the existing approved specifications.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively “Amneal”).

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2021. In addition, today the Company announced a significant cost savings initiative designed to reduce its annual costs in 2022 by at least $40 million. This figure does not include savings from, or the costs associated with, the divestiture of vitaCare, which are estimated at approximately $20 million annually.

TherapeuticsMD, Inc. (NASDAQTXMD) (TXMD or the Company), an innovative, leading women’s healthcare company, today announced key leadership changes, including the appointment of Hugh O’Dowd, the Company’s current President, as the Company’s Chief Executive Officer and member of the board of directors. Mr. O’Dowd will succeed Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.

TherapeuticsMD, Inc. (NASDAQTXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare company, today announced the appointment of Mark Glickman as the Company’s Chief Business Officer.

This September, TherapeuticsMD, Inc., an innovative women’s healthcare company (NASDAQTXMD), is recognizing Menopause Awareness Month, as it aims to empower the 64 million women in the U.S. currently in menopauseii. To celebrate this month and all menopausal women, TherapeuticsMD encourages people to Take Pause and learn about menopause.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare company, today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary recommendation to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J Code for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system). As a result, CMS established the new HCPCS Level II code J7294 “Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each,” which will allow Title X facilities to be reimbursed for dispensing ANNOVERA. The coding action will be effective October 1st, 2021.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare company, today announced the appointment of Hugh O’Dowd as President. Mr. O’Dowd succeeds John C.K. Milligan, IV, who the Company recently appointed as Chief Executive Officer of its vitaCare Prescription Services business.

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the second quarter ended June 30, 2021.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (“FDA”).

TherapeuticsMD, Inc. (NASDAQTXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage, LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization including alignment, execution, and connection.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare Company, today reported financial results for the first quarter ended March 31, 2021.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative women’s healthcare company, today announced Phase 3 menstrual bleeding profile data for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) was presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting conducted virtually from April 30 to May 2, 2021.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.

TherapeuticsMD, Inc. (NASDAQTXMD), an innovative, leading women’s healthcare company, and Theramex, a dedicated women’s health company, announced that BIJUVE® has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom and, from the Federal Agency for Medicines and Health Products (FAMHP) for use in Belgium under BIJUVA®.